Drug
Tak 928
Tak 928: highest development phase Phase 3, developed by Takeda. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Takeda
Trials
| Drug | Phase | Indication |
|---|---|---|
| TAK-928 NCT07217301 | Phase 3 | IO Resistant Squamous and Nonsquamous NSCLC |
Latest
No recent events.
Follow Tak 928 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.